{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:16:19Z","timestamp":1791278179088,"version":"4.1.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T00:00:00Z","timestamp":1340755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0032458","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T22:07:59Z","timestamp":1340834879000},"page":"e32458","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":71,"title":["Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model"],"prefix":"10.1371","volume":"7","author":[{"given":"Jennifer","family":"Perez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Val\u00e9rie","family":"Decouvelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pointecouteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pissaloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Dutour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,6,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2007-0237","article-title":"The clinical approach towards chondrosarcoma.","volume":"13","author":"H Gelderblom","year":"2008","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.2106\/00004623-200411000-00008","article-title":"Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes.","volume":"86-A","author":"ID Dickey","year":"2004","journal-title":"J Bone Joint Surg Am"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.prp.2008.12.008","article-title":"Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors.","volume":"205","author":"T Kalinski","year":"2009","journal-title":"Pathol Res Pract"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(05)70282-5","article-title":"Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment.","volume":"6","author":"JV Bovee","year":"2005","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ctrv.2008.09.006","article-title":"The role of mTOR in the management of solid tumors: an overview.","volume":"35","author":"AS Strimpakos","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-2-45","article-title":"Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.","volume":"2","author":"R Yuan","year":"2009","journal-title":"J Hematol Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.","volume":"23","author":"DC Fingar","year":"2004","journal-title":"Oncogene"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/MMBR.69.1.79-100.2005","article-title":"Signaling by target of rapamycin proteins in cell growth control.","volume":"69","author":"K Inoki","year":"2005","journal-title":"Microbiol Mol Biol Rev"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1634\/theoncologist.12-8-1007","article-title":"The biology behind mTOR inhibition in sarcoma.","volume":"12","author":"X Wan","year":"2007","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1560","article-title":"The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas.","volume":"13","author":"E Hernando","year":"2007","journal-title":"Nat Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents.","volume":"5","author":"S Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1002\/ijc.21532","article-title":"In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.","volume":"118","author":"D Ito","year":"2006","journal-title":"Int J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-06-4490","article-title":"RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.","volume":"67","author":"S Mabuchi","year":"2007","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/0008-5472.CAN-06-2449","article-title":"Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.","volume":"67","author":"CO Nathan","year":"2007","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1158\/1078-0432.CCR-09-0842","article-title":"A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.","volume":"15","author":"AE Perl","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1200\/JCO.2009.25.2981","article-title":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.","volume":"28","author":"AJ Wagner","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/CAD.0b013e328312c0e5","article-title":"Targeting the mammalian target of rapamycin in myxoid chondrosarcoma.","volume":"19","author":"O Merimsky","year":"2008","journal-title":"Anticancer Drugs"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bjc.6604269","article-title":"Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.","volume":"98","author":"R Bianco","year":"2008","journal-title":"Br J Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2008.03.024","article-title":"Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.","volume":"49","author":"AC Piguet","year":"2008","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/ijc.21951","article-title":"Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.","volume":"119","author":"F Gouin","year":"2006","journal-title":"Int J Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1158\/1078-0432.CCR-09-1249","article-title":"Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.","volume":"15","author":"P Gulhati","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-4385","article-title":"Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.","volume":"69","author":"W Zhang","year":"2009","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.","volume":"10","author":"WH Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref24","first-page":"6141","article-title":"Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.","volume":"62","author":"V Grunwald","year":"2002","journal-title":"Cancer Res"},{"key":"ref25","article-title":"Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs 22: 58\u201378.","author":"T O'Reilly","year":"2011"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.4161\/cc.9.9.11483","article-title":"The Raf\/MEK\/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.","volume":"9","author":"SL Abrams","year":"2010","journal-title":"Cell Cycle"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2008.27","article-title":"Targeting survival cascades induced by activation of Ras\/Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways for effective leukemia therapy.","volume":"22","author":"JA McCubrey","year":"2008","journal-title":"Leukemia"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.advenzreg.2008.02.006","article-title":"Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.","volume":"48","author":"JA McCubrey","year":"2008","journal-title":"Adv Enzyme Regul"},{"key":"ref29","first-page":"372","article-title":"Synergy between PI3K\/Akt and Raf\/MEK\/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells.","volume":"3","author":"JG Shelton","year":"2004","journal-title":"Cell Cycle"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.","volume":"66","author":"KE O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"38052","DOI":"10.1074\/jbc.M106703200","article-title":"Amino acid and insulin signaling via the mTOR\/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells.","volume":"276","author":"F Tremblay","year":"2001","journal-title":"J Biol Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.","volume":"26","author":"X Wan","year":"2007","journal-title":"Oncogene"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nrc2501","article-title":"Hypoxia signalling through mTOR and the unfolded protein response in cancer.","volume":"8","author":"BG Wouters","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"ref34","article-title":"Combination of PI3K\/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 71: 4573\u20134584.","author":"M Mazzoletti","year":"2011"},{"key":"ref35","article-title":"Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17: 871\u2013879.","author":"R Quek","year":"2011"},{"key":"ref36","article-title":"Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol.","author":"WS Holland","year":"2011"},{"key":"ref37","article-title":"Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res 70: 10329\u201310339.","author":"G Moriceau","year":"2010"},{"key":"ref38","article-title":"Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 119: 980\u2013984.","author":"F Gouin","year":"2006"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0032458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:39:43Z","timestamp":1642617583000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0032458"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,6,27]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0032458","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,27]]}}}